UROV

URO-902

Overactive Bladder (OAB)

Stage (next event)

Expected Date

Phase 2a (DSMB Meeting)

December 2020 / Early 2021

Catalyst Info & Data Links

TITLE: URO-902 in Overactive Bladder (OAB) - Phase 2a DSMB Meeting

  • ClinicalTrial.gov (NCT04211831): URO-902 in Female Subjects With Overactive Bladder and Urge Urinary Incontinence


WHAT IS THE NEXT CATALYST EVENT?

  • Phase 2a DSMB Meeting


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?


PRIOR DATA

PRESS RELEASES

Mechanism of Action

MECHANISM OF ACTION / RATIONALE

  • Urovant’s second investigational product candidate, URO-902 , is a novel gene therapy for patients with overactive bladder (OAB) symptoms who have failed oral pharmacologic therapy. URO-902 has been evaluated in two Phase 1 studies in OAB patients including a small, double-blind, placebo-controlled Phase 1b clinical trial as an intravesical injection in women with overactive bladder symptoms. Ion Channel Innovations completed the Phase 1b study in 2017 and found URO-902 to be generally well tolerated. Efficacy results of the trial, which included a limited number of patients (n=13), indicated dose-dependent improvements in urinary urgency and frequency, achieving statistical significance (p<0.05) in the high dose cohort. Urovant expects to initiate a Phase 2 URO-902 study in 2019 (Learn more HERE). 


Updated by HC

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See what the community is saying - click to see full post

UROV's Vibegron Imminent Phase 3 Readout In Overactive Bladder Has a Good Chance of Success

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon